Research ArticleNuclear Oncology
Pharmacokinetic Model of Iodine-131-G250 Antibody in Renal Cell Carcinoma Patients
Angela Loh, George Sgouros, Joseph A. O'Donoghue, Devie Deland, Dennis Puri, Peter Capitelli, John L. Humm, Steven M. Larson, Lloyd J. Old and Chaitanya R. Divgi
Journal of Nuclear Medicine March 1998, 39 (3) 484-489;
Angela Loh
George Sgouros
Joseph A. O'Donoghue
Devie Deland
Dennis Puri
Peter Capitelli
John L. Humm
Steven M. Larson
Lloyd J. Old


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Pharmacokinetic Model of Iodine-131-G250 Antibody in Renal Cell Carcinoma Patients
Angela Loh, George Sgouros, Joseph A. O'Donoghue, Devie Deland, Dennis Puri, Peter Capitelli, John L. Humm, Steven M. Larson, Lloyd J. Old, Chaitanya R. Divgi
Journal of Nuclear Medicine Mar 1998, 39 (3) 484-489;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Parametric Images of Antibody Pharmacokinetics Based on Serial Quantitative Whole-Body Imaging and Blood Sampling
- Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer
- Red Marrow Radiation Dose Adjustment Using Plasma FLT3-L Cytokine Levels: Improved Correlations Between Hematologic Toxicity and Bone Marrow Dose for Radioimmunotherapy Patients